-
Eltanexor: A Compartment-First Research Strategy
2026-09-22
Eltanexor (KPT-8602) is more than an XPO1 inhibitor: it is a tool for testing how nuclear protein localization reshapes cancer biology. This article translates evidence from leukemia, lymphoma, and colorectal cancer models into practical assay and study-design decisions.
-
FCCP B5004: Reliable Mitochondrial Assays
2026-09-22
A scenario-based guide to using FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone), SKU B5004, in viability, proliferation, cytotoxicity, and HIF-pathway experiments. It covers mechanism, assay compatibility, dose optimization, data interpretation, and practical supplier selection.
-
RSL3 and the Ferroptosis Translation Gap
2026-09-21
RSL3 is more than a ferroptosis inducer: it is a mechanistic probe for testing whether GPX4-dependent redox buffering creates actionable vulnerabilities in RAS-driven tumors and radioresistant disease. This article connects GPX4 inhibition with the HIF-1α-HILPDA axis in nasopharyngeal carcinoma and outlines a disciplined path from experimental validation to translational decision-making.
-
LMO2–LDB1 Signaling in Acute Myeloid Leukemia
2026-09-21
The reference study identifies an LMO2/LDB1 protein complex as a functional driver of acute myeloid leukemia cell growth and survival. By combining gene perturbation, interaction proteomics, transcriptomics, chromatin profiling, and rescue experiments, it positions LDB1 as an important regulator of AML biology and clarifies how LMO2 contributes to this circuitry.
-
Taihangia rupestris: Wild vs Cultivated Bioactivity
2026-09-20
This 2026 study integrates UPLC-MS/MS chemical profiling with orthogonal antioxidant, α-glucosidase inhibition, online HPLC-ABTS, ultrafiltration-LC/MS, and molecular docking analyses to compare wild and cultivated Taihangia rupestris leaves. Foothill cultivation produced the strongest chemical and functional profile, supporting cultivation as a conservation-compatible source for natural product antioxidant evaluation and antidiabetic lead discovery.
-
Autophagy Modulates Resveratrol Apoptosis in RCC
2026-09-19
The reference study shows that resveratrol induces ROS-associated mitochondrial apoptosis and caspase-3 activation in renal cell carcinoma 786-O cells, while simultaneously triggering JNK-linked autophagy. Its central implication is that autophagy acts as a protective response, suggesting that combining resveratrol with autophagy inhibition may intensify tumor-cell killing in this experimental model.
-
EZ Cap™ Firefly Luciferase mRNA: Translation Insight
2026-09-18
A mechanistic guide to using Cap1 firefly luciferase mRNA as a controlled system for separating delivery, translation, RNA stability, and cellular response in translational research.
-
NSP15 Inhibitor Screening: Thymopentin and Oleuropein
2026-09-18
A 2021 structure-based study screened a natural-product library against the SARS-CoV-2 endoribonuclease NSP15 and identified thymopentin and oleuropein as leading computational hits. Molecular-dynamics analysis supported stable protein–ligand complexes, while the study also highlights the need for biochemical and cellular validation before therapeutic conclusions can be drawn.
-
Palmitic acid (N2456): Practical Protocol Guide
2026-09-17
This guide provides solvent selection, storage, preparation, and QC guidance for Palmitic acid (hexadecanoic acid) in lipid and cell-based research. The product is suited to freshly prepared ethanol- or DMSO-based workflows, but not to direct aqueous dissolution or long-term storage of prepared solutions.
-
Mifepristone (RU486): Applied Research Workflows
2026-09-17
Build reproducible progesterone-receptor assays with Mifepristone (RU486), from solvent handling and dose–response design to receptor-stratified cancer experiments. The workflow connects ovarian, meningioma, reproductive, and heterogeneous prostate cancer models while separating established evidence from practical assay extensions.
-
Coelenterazine: From ROS Signal to Translational Insight
2026-09-16
Coelenterazine can do more than generate a bright luminescent readout: when its chemistry, reporter biology, and controls are aligned, it can help translational researchers connect reactive oxygen species with disease mechanism. This article develops an assay strategy informed by brain–kidney AVP research and cancer-associated ROS imaging.
-
GSK126: Assay Logic for EZH2-Driven Resistance
2026-09-16
GSK126 is a selective EZH2 inhibitor for dissecting how epigenetic state, ETV5 activity, and PRC2 dependence shape cancer-cell responses. This guide translates a recent pan-cancer study into practical assay decisions for cancer epigenetics research and oncology drug development.
-
Trichostatin A: Context-Resolved HDAC Biology
2026-09-15
Explore how Trichostatin A (TSA) links histone acetylation to cancer phenotypes, dendritic-cell metabolism, and assay design. This evidence-driven guide emphasizes context-resolved interpretation rather than endpoint-only HDAC inhibition.
-
Ziprasidone Targets GOT1 in Pancreatic Cancer
2026-09-15
The reference study identifies ziprasidone as a noncompetitive GOT1 inhibitor that disrupts glutamine-dependent redox metabolism in pancreatic ductal adenocarcinoma. Its combination of biochemical, cellular, metabolomic, genetic, and xenograft evidence supports GOT1 as a therapeutic vulnerability while also defining important limits for translation.
-
EdU Cell Proliferation Kit for RA S-Phase Studies
2026-09-14
Translate ARL4C-linked synoviocyte biology into direct DNA-synthesis data with a non-radioactive, TMB-based workflow. This 5-ethynyl-2'-deoxyuridine proliferation assay supports rheumatoid arthritis research, genotoxicity testing, and pharmacodynamic drug evaluation while preserving practical plate-reader throughput.